<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881838</url>
  </required_header>
  <id_info>
    <org_study_id>CCCG-ALCL-2020</org_study_id>
    <nct_id>NCT04881838</nct_id>
  </id_info>
  <brief_title>CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL</brief_title>
  <official_title>Using a Modified ALCL99 Regimen for Chinese Children With Newly Diagnosed High-risk Anapestic Large Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Cancer Group, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Children's Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>1st Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Cancer Group, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the&#xD;
      current Chinese pediatric and adolescent high-risk ALCL and compared with our historical&#xD;
      data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anaplastic large cell lymphoma (ALCL) accounts for 15% of pediatric and adolescent&#xD;
      non-Hodgkin lymphomas (NHLs). In our historical study (retrospective multicenter study), the&#xD;
      3-year event-free survival (EFS) was 65% for 80 eligible patients treated in 10 centers&#xD;
      between January 2009 and June 2014.&#xD;
&#xD;
      The ALCL99 trial reported a 2-year overall survival of 92% and 2-year event-free survival of&#xD;
      74% then become the current standard frontline treatment for pediatric ALCL. The recent&#xD;
      long-term follow-up data from ALCL99 trial highlighted its excellent outcome. A less toxic&#xD;
      schedule of methotrexate (MTX) 3g/m2 in a 3-hour infusion without intrathecal therapy&#xD;
      reproduced the favorable results from previous reports of NHL-BFM90 protocol with MTX at&#xD;
      1g/m2 in a 3-hour infusion. Additionally, a prospective ALCL-Relapse trial by the European&#xD;
      Inter-Group for Childhood Non-Hodgkin Lymphoma demonstrated 80% of patients with a late&#xD;
      relapse can be cured by 24 months of vinblastine monotherapy. However, vinblastine would not&#xD;
      be advised as a treatment option in mainland China due to its inaccessibility. A pilot&#xD;
      experience using single-drug vinorelbine in 4 pediatric patients with relapsed ALCL with&#xD;
      satisfactory outcome provides the rational for studying vinorelbine as a front line drug&#xD;
      option.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All enrolled patients stratified into high risk group are assigned to one treatment regimen</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year event free survival (EFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Calculated from the time of diagnosis to the first of the following events: progression, relapse, secondary ,malignancy or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAEv5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Pediatric Anaplastic Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>High risk group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stage I, unresected; Stage I with &quot;B&quot; syndrome&#xD;
Stage II&#xD;
Stage III&#xD;
Stage IV without CNS involvement</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>P regimen</intervention_name>
    <description>Dexamethasone 5 mg/m2 Days 1 and 2; 10mg/m2 Day 3 to 5; Cyclophosphamide 200 mg/m2 Days 1 and 2 Intrathecal therapy Day 1</description>
    <arm_group_label>High risk group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Course A1 + Vin</intervention_name>
    <description>vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;</description>
    <arm_group_label>High risk group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Course B1 +Vin</intervention_name>
    <description>vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;</description>
    <arm_group_label>High risk group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Course A2 + Vin</intervention_name>
    <description>vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;</description>
    <arm_group_label>High risk group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Course B2 +Vin</intervention_name>
    <description>vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;</description>
    <arm_group_label>High risk group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Course A3 + Vin</intervention_name>
    <description>vinorelbine 25 mg/m2, Day 1 Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Etoposide 100mg/m2, Days 4 to 5; Ifosfamide 800 mg/m2, Days 1 to 5; Cytarabine 150 mg/m2, q12h Days 4 to 5;</description>
    <arm_group_label>High risk group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Course B3 +Vin</intervention_name>
    <description>vinorelbine 25 mg/m2, Day 1; Dexamethasone 10 mg/m2 Days 1 to 5; Methotrexate 3g/m2, 3-hour infusion Day 1; Cyclophosphamide 200 mg/m2, Days 1 to 5; Doxorubicin 25 mg/m2, Days 4 to 5;</description>
    <arm_group_label>High risk group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maintenance therapy</intervention_name>
    <description>Vinorelbine 25 mg/m2 IV, weekly for 3 consecutive weeks followed by 1-week rest. Totally 80 cycles.</description>
    <arm_group_label>High risk group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be â‰¤ 18 years at the time of diagnosis&#xD;
&#xD;
          -  Newly diagnosed patients with histologically confirmed high-risk anaplastic large cell&#xD;
             lymphoma&#xD;
&#xD;
          -  No congenital immunodeficiency, HIV infection, or prior organ transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have received prior cytotoxic chemotherapy/target therapy/radiation, if any&#xD;
             steroid applied, total prior steroids dosage &gt; Dexamethasone 40 mg/m2 for the current&#xD;
             diagnosis or any cancer&#xD;
&#xD;
          -  Patients have overwhelming infection, and a life expectancy of &lt; 2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yijin Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qing Yuan, MD</last_name>
    <phone>+8613062865879</phone>
    <email>1832975884@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yali Han, MD</last_name>
    <phone>+8613661574996</phone>
    <email>hanyali@scmc.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yali Han</last_name>
      <phone>+8613661574996</phone>
      <email>hanyali@scmc.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Mussolin L, Le Deley MC, Carraro E, Damm-Welk C, Attarbaschi A, Williams D, Burke A, Horibe K, Nakazawa A, Wrobel G, Mann G, CsÃ³ka M, Uyttebroeck A, FernÃ¡ndez-Delgado CerdÃ¡ RF, Beishuizen A, Mellgren K, Burkhardt B, Klapper W, Turner SD, D'Amore ESG, Lamant L, Reiter A, Woessmann W, BrugiÃ¨res L, Pillon MPOBOTEIFCNL. Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial. Cancers (Basel). 2020 Sep 24;12(10). pii: E2747. doi: 10.3390/cancers12102747.</citation>
    <PMID>32987765</PMID>
  </results_reference>
  <results_reference>
    <citation>KnÃ¶rr F, BrugiÃ¨res L, Pillon M, Zimmermann M, Ruf S, Attarbaschi A, Mellgren K, Burke GAA, Uyttebroeck A, WrÃ³bel G, Beishuizen A, Aladjidi N, Reiter A, Woessmann W; European Inter-Group for Childhood Non-Hodgkin Lymphoma. Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial. J Clin Oncol. 2020 Dec 1;38(34):3999-4009. doi: 10.1200/JCO.20.00157. Epub 2020 Jul 30.</citation>
    <PMID>32730187</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuan Q, He Q, Mi Q, Yin MZ, Han YL, Gao YJ. Single-drug vinorelbine as a salvage re-induction regimen for 4 consecutive pediatric patients with relapsed anaplastic large-cell lymphoma in a single children's institution. Ann Hematol. 2021 Apr;100(4):1093-1095. doi: 10.1007/s00277-020-04175-3. Epub 2020 Jul 13.</citation>
    <PMID>32661576</PMID>
  </results_reference>
  <results_reference>
    <citation>Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, Zsiros J, Uyttebroeck A, Marky IM, Lamant L, Woessmann W, Pillon M, Hobson R, Mauguen A, Reiter A, BrugiÃ¨res L. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010 Sep 1;28(25):3987-93. doi: 10.1200/JCO.2010.28.5999. Epub 2010 Aug 2.</citation>
    <PMID>20679620</PMID>
  </results_reference>
  <results_reference>
    <citation>BrugiÃ¨res L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009 Feb 20;27(6):897-903. doi: 10.1200/JCO.2008.18.1487. Epub 2009 Jan 12.</citation>
    <PMID>19139435</PMID>
  </results_reference>
  <results_reference>
    <citation>Lymphoma Study Group, Subspecialty Group of Hematology, the Society of Pediatrics, Chinese Medical Association; Lymphoma Study Group, Committee of Pediatrics, Chinese Anti-Cancer Association. [Diagnosis and treatment of anaplastic large-cell lymphoma in children and adolescents: a retrospective multicenter survey study]. Zhonghua Er Ke Za Zhi. 2017 Mar 2;55(3):194-199. doi: 10.3760/cma.j.issn.0578-1310.2017.03.006. Chinese.</citation>
    <PMID>28273702</PMID>
  </results_reference>
  <results_reference>
    <citation>MossÃ© YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM, Weigel BJ. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017 Oct 1;35(28):3215-3221. doi: 10.1200/JCO.2017.73.4830. Epub 2017 Aug 8.</citation>
    <PMID>28787259</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anapestic Large Cell Lymphoma</keyword>
  <keyword>vinorelbine</keyword>
  <keyword>pediatric</keyword>
  <keyword>treatment outcome</keyword>
  <keyword>Chinese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Study protocol, SAP and ICF were shared before study initiation. Patient data and the information about the process of the study will be shared within the all participants annually after enrollment patients.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be shared within the all hospitals every 12 months after enrollment of patients.</ipd_time_frame>
    <ipd_access_criteria>Scheduled meeting and paper transferring.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

